Abstracts tagged "arthroplasty and outcomes"

Abstract Number: 150 • 2015 ACR/ARHP Annual Meeting
A Preliminary Consensus on Core Outcome Domains for Total Joint Replacement Clinical Trials: An Omeract-Based Study
Jasvinder A. Singh¹ and Michael Dohm², ¹University of Alabama at Birmingham, Birmingham, AL, ²Orthopaedic Surgery, Univ of Arizona, Tucson, AZ, Tucson, AZ
Background/Purpose: Outcomes Measures in Rheumatology Trials (OMERACT) has developed a framework based on the WHO’s International Classification of Functioning, Disability, and Health (ICF) conceptual model. …
Abstract Number: 1278 • 2015 ACR/ARHP Annual Meeting
An Underlying Diagnosis of Osteoarthritis Is Associated with Better Outcomes after Total Hip Arthroplasty Than Avascular Necrosis of Bone
Jasvinder A. Singh¹, Jason Chen², Maria Inacio², Robert Namba² and Elizabeth Paxton², ¹University of Alabama at Birmingham, Birmingham, AL, ²Kaiser Permanente, San Diego, CA
Background/Purpose: We recently showed that underlying diagnosis of RA was associated with higher readmission rate compared to osteoarthritis. Studies of adequate sample size assessing post-THA…
Abstract Number: 1419 • 2015 ACR/ARHP Annual Meeting
Increasing Comorbidity Is Associated with Worsening Physical Function during Intermediate-Term Follow-up of Primary Total Knee Arthroplasty
Maren Hilton¹, Terence Gioe² and Jasvinder A. Singh³, ¹Arthritis and Rheumatology Consultants, Edina, MN, ²Department of Orthopaedic Surgery, Minneapolis VA Medical Center, Minneapolis, MN, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Total knee arthroplasty (TKA) is associated with significant gains in function and pain improvement. However, decline in function has been noted in patients who…
Abstract Number: 199 • 2014 ACR/ARHP Annual Meeting
Increasing Complexity of Patients Undergoing Primary Total Hip Arthroplasty in the U.S
Jasvinder A. Singh¹ and David Lewallen², ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Orthopedics, Mayo Clinic college of medicine, Rochester, MN
Background/Purpose: To examine the time-trends in key demographic and clinical characteristics of patients undergoing primary total hip arthroplasty (THA).Methods: We used the data from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].